

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Comparison of the effect of probiotics on the prevention of diarrhea in two groups of patients treated with antibiotics and patients treated with antibiotics and probiotics

#### Protocol summary

##### Study aim

The effect of probiotics in preventing diarrhea caused by antibiotics

##### Design

Clinical trials with 2 groups of 150 parallel, with controlled group, single blind, randomized by random numbers

##### Settings and conduct

The study will be done as a single-blind form. 300 patients aged between 18-94 years old who were referred to infectious clinics of Sina and Imam Reza Hospital and Sheikh Al-Reyes Clinic in Tabriz from 4.4.2017 to 3.6.2018 and need to be treated with antibiotics for any reason, will be selected and informed upon completion of informed consent form. Samples are divided into groups of Intervention and Placebo by random numbers and will take medication or placebo. Patients are advised blind about taking the medication or placebo, and they will not know the contents of the pack (medication or placebo). The Probiotic drug used in this design is a capsule containing *Saccharomyces cerevisiae* brand Yomogi 250 mg. In the control group, 250 mg of lactose-free dry milk will be used in capsules similar to the Probiotic.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 1- The age range is 18-94 years 2- Receiving antibiotics for any cause 3. Informed consent of Patients to Participate in the Study. Exclusion criteria: 1- Patients with diarrhea at home 2- Patients with any pathological illness that causes diarrhea 3- History of intestinal surgery 4- Rheumatism and endocarditis 5- Patients treated with laxative 6- Antibiotic use over the past 2 weeks 7- Patients with artificial valve and immune deficiency

##### Intervention groups

All patients who have been referred to the infectious clinics of Sina and Imam Reza hospitals and Shaikh-e-Reyes Clinic of Tabriz from 4.4.2017 to 3.6.2018 are

treated with antibiotics for any reason. They were divided into two groups. They receive an antibiotic and a group of antibiotics and probiotics.

##### Main outcome variables

Diarrhea; colitis

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180805040711N1**

Registration date: **2018-09-15, 1397/06/24**

Registration timing: **retrospective**

Last update: **2018-09-15, 1397/06/24**

Update count: **0**

##### Registration date

2018-09-15, 1397/06/24

##### Registrant information

##### Name

Seyyed Mehdi Haghdoost

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 3337 5411

##### Email address

haghdoostm@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2017-04-04, 1396/01/15

##### Expected recruitment end date

2018-03-06, 1396/12/15

**Actual recruitment start date**

2017-04-04, 1396/01/15

**Actual recruitment end date**

2018-03-06, 1396/12/15

**Trial completion date**

empty

**Scientific title**

Comparison of the effect of probiotics on the prevention of diarrhea in two groups of patients treated with antibiotics and patients treated with antibiotics and probiotics

**Public title**

The effect of Probiotics in the prevention of diarrhea caused by antibiotics

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

The age range is 18-94 years Need to get antibiotics for any cause Conscious Consciousness of Patients to Participate in the Study

**Exclusion criteria:**

Patients with diarrhea at the time of admission Patients with any pathological illness that causes diarrhea History of intestinal surgery Rheumatism and endocarditis Patients treated with laxative Patients who have had antibiotic use in the last 2 weeks Patients with artificial valve and immune deficiency

**Age**

From **18 years** old to **94 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant

**Sample size**

Target sample size: **300**

Actual sample size reached: **300**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The sampling method will be simple random. The samples will be randomly divided by random numbers into two groups of intervention group and placebo group (150 in each group).

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

The study will be done as a single-blind form. The Probiotic drug used in this design is a capsule containing Saccharomyces Cerevisiae brand Yomogi 250 mg. In the control group, 250 mg of lactose-free dry milk will be used in capsules similar to the Probiotic capsules. Capsules will be packaged and coded. Samples are divided into groups of intervention group and placebo group by random numbers. Patients are blinded about taking the medication or placebo, and they will not know the contents of the pack (medication or placebo).

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tabriz University of Medical Science (Human Subjects Studies)

**Street address**

Gholghasht Ave, Tabriz City

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5165665931

**Approval date**

2018-07-23, 1397/05/01

**Ethics committee reference number**

IR.TBZMED.REC.1397.359

**Health conditions studied****1****Description of health condition studied**

Diarrhea caused by antibiotics

**ICD-10 code**

K59.1

**ICD-10 code description**

Functional diarrhea

**Primary outcomes****1****Description**

The volume and frequency of antibiotic-induced diarrhea

**Timepoint**

The beginning of the treatment (before the intervention), during and two weeks after treatment

**Method of measurement**

Checklist designed in the study (The frequency of diarrhea is over 3 times and the volume of diarrhea is about 200 grams per day)

**Secondary outcomes**

empty

## Intervention groups

### 1

#### Description

Intervention group: The Probiotic drug capsule containing Saccharomyces cerevisiae brand Yomogi 250 mg

#### Category

Prevention

### 2

#### Description

Control group: 250 mg of lactose-free dry milk will be used in capsules similar to the Probiotic capsule

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Imam Reza hospital

##### Full name of responsible person

Dr.Seyed Mehdi Haghdoost

##### Street address

Gholghasht Ave, Tabriz City

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166615745

##### Phone

+98 41 3334 7056

##### Email

info@imamreza.tbzmed.ac.ir

##### Web page address

### 2

#### Recruitment center

##### Name of recruitment center

Sina hospital

##### Full name of responsible person

Dr.Seyed Mehdi Haghdoost

##### Street address

Azadi Ave, Tabriz City

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166615163

##### Phone

+98 41 3549 8140

##### Email

info@sinahosp.tbzmed.ac.ir

### 3

#### Recruitment center

##### Name of recruitment center

Sheikholraies clinic

##### Full name of responsible person

Dr.Seyed Mehdi Hghdoost

##### Street address

Azadi Ave, Tabriz City

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166615543

##### Phone

+98 41 3336 6215

##### Email

info@shaclinic.tbzmed.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Tabriz University of Medical Sciences

##### Full name of responsible person

Dr.Abolghasem Jouyban

##### Street address

Tabriz Univercity of Medical Science,Daneshghah Street, Tabriz City

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5165687386

##### Phone

+98 41 3335 7310

##### Email

Ajouyban@hotmail.com

##### Web page address

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Tabriz University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

haghdstm@tbzmed.ac.ir

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr.Seyed Mehdi Haghdoost

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Infectious diseases

**Street address**

Medicine Faculty, Ghoghasht Ave, Tabriz City

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5165687386

**Phone**

+98 41 3334 1249

**Email**

haghdstm@tbzmed.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr.Seyed Mehdi Haghdoost

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Infectious diseases

**Street address**

Medicine Faculty, Ghoghasht Ave, Tabriz City

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5165687386

**Phone**

+98 41 3334 1249

**Email**

## Person responsible for updating data

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr.Seyed Mehdi Haghdoost

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Infectious diseases

**Street address**

Medicine Faculty, Gholghasht Ave, Tabriz City

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5165687386

**Phone**

+98 41 3334 1249

**Email**

haghdstm@tbzmed.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available